vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and VICOR CORP (VICR). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $113.0M, roughly 1.6× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs 0.9%, a 17.4% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 20.2%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 14.7%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
FOLD vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $113.0M |
| Net Profit | $1.7M | $20.7M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | 59.7% |
| Net Margin | 0.9% | 18.3% |
| Revenue YoY | 23.7% | 20.2% |
| Net Profit YoY | -88.5% | 713.9% |
| EPS (diluted) | $0.00 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $185.2M | $107.3M | ||
| Q3 25 | $169.1M | $110.4M | ||
| Q2 25 | $154.7M | $96.0M | ||
| Q1 25 | $125.2M | $94.0M | ||
| Q4 24 | $149.7M | $96.2M | ||
| Q3 24 | $141.5M | $93.2M | ||
| Q2 24 | $126.7M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $1.7M | $46.5M | ||
| Q3 25 | $17.3M | $28.3M | ||
| Q2 25 | $-24.4M | $41.2M | ||
| Q1 25 | $-21.7M | $2.5M | ||
| Q4 24 | $14.7M | $10.2M | ||
| Q3 24 | $-6.7M | $11.6M | ||
| Q2 24 | $-15.7M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | 55.4% | ||
| Q3 25 | 88.5% | 57.5% | ||
| Q2 25 | 90.2% | 95.9% | ||
| Q1 25 | 90.7% | 47.2% | ||
| Q4 24 | 90.1% | 52.4% | ||
| Q3 24 | 90.6% | 49.1% | ||
| Q2 24 | 91.1% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 8.6% | 14.6% | ||
| Q3 25 | 20.3% | 18.9% | ||
| Q2 25 | -6.1% | 47.3% | ||
| Q1 25 | -6.3% | -0.2% | ||
| Q4 24 | 10.7% | 9.6% | ||
| Q3 24 | 15.3% | 5.8% | ||
| Q2 24 | 11.8% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 0.9% | 43.4% | ||
| Q3 25 | 10.2% | 25.6% | ||
| Q2 25 | -15.8% | 42.9% | ||
| Q1 25 | -17.3% | 2.7% | ||
| Q4 24 | 9.8% | 10.7% | ||
| Q3 24 | -4.8% | 12.4% | ||
| Q2 24 | -12.4% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.00 | $1.01 | ||
| Q3 25 | $0.06 | $0.63 | ||
| Q2 25 | $-0.08 | $0.91 | ||
| Q1 25 | $-0.07 | $0.06 | ||
| Q4 24 | $0.05 | $0.24 | ||
| Q3 24 | $-0.02 | $0.26 | ||
| Q2 24 | $-0.05 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $404.2M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $754.1M |
| Total Assets | $949.9M | $804.9M |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $293.5M | $402.8M | ||
| Q3 25 | $263.8M | $362.4M | ||
| Q2 25 | $231.0M | $338.5M | ||
| Q1 25 | $250.6M | $296.1M | ||
| Q4 24 | $249.9M | $277.3M | ||
| Q3 24 | $249.8M | $267.6M | ||
| Q2 24 | $260.1M | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $274.2M | $711.6M | ||
| Q3 25 | $230.4M | $630.1M | ||
| Q2 25 | $204.3M | $608.6M | ||
| Q1 25 | $193.6M | $580.3M | ||
| Q4 24 | $194.0M | $570.1M | ||
| Q3 24 | $178.8M | $554.6M | ||
| Q2 24 | $132.5M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $949.9M | $785.8M | ||
| Q3 25 | $868.8M | $710.2M | ||
| Q2 25 | $815.3M | $693.5M | ||
| Q1 25 | $789.8M | $665.0M | ||
| Q4 24 | $785.0M | $641.1M | ||
| Q3 24 | $786.6M | $632.8M | ||
| Q2 24 | $749.5M | $613.2M |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.3M | $15.7M | ||
| Q3 25 | $35.7M | $38.5M | ||
| Q2 25 | $-26.5M | $65.2M | ||
| Q1 25 | $7.8M | $20.1M | ||
| Q4 24 | $-3.9M | $10.1M | ||
| Q3 24 | $-23.0M | $22.6M | ||
| Q2 24 | $22.7M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $10.2M | ||
| Q3 25 | $35.3M | $34.5M | ||
| Q2 25 | $-28.9M | $59.0M | ||
| Q1 25 | $7.5M | $15.6M | ||
| Q4 24 | $-4.2M | $8.4M | ||
| Q3 24 | $-23.3M | $14.1M | ||
| Q2 24 | $21.6M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | 9.5% | ||
| Q3 25 | 20.9% | 31.2% | ||
| Q2 25 | -18.7% | 61.5% | ||
| Q1 25 | 6.0% | 16.6% | ||
| Q4 24 | -2.8% | 8.7% | ||
| Q3 24 | -16.5% | 15.2% | ||
| Q2 24 | 17.0% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 5.2% | ||
| Q3 25 | 0.2% | 3.6% | ||
| Q2 25 | 1.6% | 6.5% | ||
| Q1 25 | 0.2% | 4.8% | ||
| Q4 24 | 0.2% | 1.8% | ||
| Q3 24 | 0.3% | 9.1% | ||
| Q2 24 | 0.9% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | 0.34× | ||
| Q3 25 | 2.06× | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | -0.27× | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
